NCT05593601 is a Phase 4 clinical trial of Neomycin in Colonization, Asymptomatic, sponsored by Mahidol University.

Who is sponsoring NCT05593601?

NCT05593601 is sponsored by Mahidol University.

What drugs are being tested in NCT05593601?

Interventions in NCT05593601: Neomycin.

What condition does NCT05593601 study?

NCT05593601 studies Colonization, Asymptomatic.

Is NCT05593601 still recruiting?

NCT05593601 is currently status unknown. Last updated 30 November 2022.

Last reviewed 2022-11-30 · How we verify

NCT05593601

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Decolonization of Carbapenem-resistant Enterobacterales (CRE) in Patients With Faecal Carriage of CRE With Neomycin

Status unknown Phase 4 Last updated 30 November 2022

What this trial tests

Phase 4 trial testing Neomycin in Colonization, Asymptomatic in 60 participants. Status unknown.

Timeline

24 November 2022

Primary endpoint
31 December 2023

31 March 2024

Quick facts

Lead sponsor	Mahidol University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	24 November 2022
Primary completion	31 December 2023
Estimated completion	31 March 2024
Sites	1 location across Thailand

Drugs / interventions tested

Neomycin (NEOMYCIN) — full drug profile →

Conditions studied

Colonization, Asymptomatic — all drugs for Colonization, Asymptomatic →

Sponsor

Mahidol University

Who can join

Adults 18 to 95, any sex, with Colonization, Asymptomatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rates of antimicrobial resistance are increasing worldwide. There is increasing evidence that physiological gut microbiota is a large reservoir of antibiotic-resistance genes. Healthy gut microbiota is known to prevent the colonization of the gastrointestinal tract by pathogens, the so-called mechanism of colonization resistance, but this protective mechanism can be altered by therapies that impair gut microbiota, including antibiotics with consequent colonization of gut pathogens, including carbapenem-resistant Enterobacterales (CRE). CRE carriers represent an epidemiological threat to other hospitalized patients and to the whole community, but are also at risk of developing clinical consequences of this colonization, including bloodstream infections from these pathogens. Neomycin has shown high efficacy in the eradication of CRE invitro. Neomycin has also been approved to treat hepatic coma by eradicating bacterial in gastrointestinal tract. Therefore, this evidence suggests that this procedure could be useful in eradicating CRE. However, current evidence is mostly limited. The aim of this study is to investigate the efficacy of Neomycin, compared with no intervention in eradicating gut colonization from CRE.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and Safety of Oral Neomycin for the Decolonization of Carbapenem-Resistant <i>Enterobacterales</i>: An Open-Label Randomized Controlled Trial.
Tancharoen L, Srisomnuek A, Tiengrim S, Thamthaweechok N, et al · · 2024 · PMID 39200081 · DOI 10.3390/antibiotics13080781

Verify or expand the search:

Other trials of Neomycin

Trials testing the same drug.

NCT07286851 — Do Topical Antibiotics Improve Skin Graft Results? · completed
NCT03593252 — Bowel Preparation in Elective Pediatric Colorectal Surgery · NA · unknown
NCT04729322 — Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of M · Phase 2 · active not recruiting
NCT03476317 — Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease · Phase 2 · completed

Other recruiting trials for Colonization, Asymptomatic

Currently open trials in the same condition.

NCT06633588 — Decolonization Efficacy of Polyhexanide vs. Mupirocin · Phase 4 · recruiting

Other Mahidol University trials

Trials by the same sponsor.

NCT07568496 — Greater Occipital Nerve Block for Migraine With Medication Overuse Headache · NA · not yet recruiting
NCT07407400 — Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients · Phase 4 · not yet recruiting
NCT07378501 — Thai Version of the Pediatric Quality of Recovery Score (PedSQoR): Translation and Psychometric Validation Study · not yet recruiting
NCT07438301 — Septic Shock Hemodynamic Respond to Volume Resuscitation Versus Vasopressor Administration · not yet recruiting
NCT07390006 — Enabling Patient-Reported Outcomes Through Innovative Care - ACS (EPIC-ACS) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05593601 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mahidol University
Last refreshed: 30 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05593601.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing